clinical trial · NCT05415137
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
aTyr Pharma, Inc.·phase3·active not recruiting·n = 268
Pulmonary SarcoidosisEfzofitimod 3 mg/kgEfzofitimod 5 mg/kgPlacebo
brief summary
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
started
Sep 15, 2022
primary completion
Jul 31, 2025
completion
Aug 31, 2025
last updated
May 20, 2025
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol